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To the Editor:
We read the article by Roberts and colleagues 1 with interest. Although we agree that hypocapnia has been demonstrated to be common and is a predictor of poor neurological outcome after cardiac arrest, we are concerned that the findings may lack external validity.
In a recent study involving 16 542 patients admitted to 125 Australian and New Zealand intensive care units after cardiac arrest between 2000 and 2011, 2 we found that hypocapnia and hypercapnia were common. Importantly, we also found that compared with normocapnia, hypercapnia was associated with a greater likelihood of discharge home among survivors. Such findings suggest that mild hypercapnia may actually have neuroprotective properties during the immediate postresuscitation phase.
We note that the median number of Paco 2 measurements assessed per patient was only 2 (interquartile range, 1-4) and that 83% of cardiac arrests occurred in hospital. 1 In our institution, the median number of arterial blood gas tests per patient is 9 (interquartile range, 7-10) during the first intensive care unit day, and our proportion of in-hospital cardiac arrest is only 35%, suggesting a much greater level of physiological monitoring and management of a very different population in Australian and New Zealand intensive care units. Moreover, mortality in the US cohort was 68% compared with 55.6% in Australia and New Zealand, and unfavorable neurological outcome was seen in 74% of survivors compared with only 35.3% of patients failing to be discharged home in Australia and New Zealand.
2 Thus, the findings of Roberts and colleagues may reflect local clinical management practices that differ profoundly from other settings internationally and should be interpreted with great caution.
Although we agree that hypocapnia should be avoided, we urge caution in implementing policies of deliberate avoidance of hypercapnia in the immediate postresuscitation phase. Moreover, we believe that there is sufficient evidence to justify phase 1 pilot randomized, controlled trials of therapeutic hypercapnia in patients who survive cardiac arrest and require mechanical ventilation. We have now initiated such a trial (Australian New Zealand clinical Trial Registry No. AcTRN1262000690853).
